Synergistic Effects of Sanglifehrin-Based Cyclophilin Inhibitor NV651 with Cisplatin in Hepatocellular Carcinoma

Synergistic Effects of Sanglifehrin-Based Cyclophilin Inhibitor NV651 with Cisplatin in Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC), commonly diagnosed at an advanced stage, is the most common primary liver cancer. Owing to a lack of effective HCC treatments and the commonly acquired chemoresistance, novel therapies need to be investigated. Cyclophilins—intracellular proteins with peptidyl-prolyl i...

Full description

Bibliographic Details
Main Authors: Sonia Simón Serrano, Michele Tavecchio, Josef Mallik, Alvar Grönberg, Eskil Elmér, Chamseddine Kifagi, Philippe Gallay, Magnus Joakim Hansson, Ramin Massoumi
Format: Article
Language:English
Published: MDPI AG 2022-09-01
Series:Cancers
Subjects:
synergy
cyclophilin
PPIase
apoptosis
hepatocellular carcinoma
cisplatin
Online Access:https://www.mdpi.com/2072-6694/14/19/4553

Similar Items

Similar Items